A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

NCT ID: NCT03718468

Last Updated: 2019-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 842 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-30
• Study Completion Date: 2019-07-03

Brief Summary

This study aims to demonstrate the immunogenic efficacy of GC FLU Quadrivalent Pre-filled Syringe inj. (GC FLU), a quadrivalent influenza virus vaccine, is non-inferior to the active control, Fluarix Tetra. This study is designed to be a randomized, open-labelled, active-controlled, parallel, phase III study recruiting subjects from multiple study sites.

Approximately 840 eligible subjects are planned to enroll in order to obtain 800 evaluable (= per-protocol) subjects. Subjects will be randomized and assigned to GC FLU or Fluarix Tetra (active control, AC) group in 1:1 ratio.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

GC Flu Quadrivalent

Group Type: EXPERIMENTAL

GC FLU Quadrivalent

Intervention Type: BIOLOGICAL

A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.

Fluarix tetra

Group Type: ACTIVE_COMPARATOR

Fluarix Tetra

Intervention Type: BIOLOGICAL

A single dose administration of Fluarix Tetra will be through intramuscular injection.

Interventions

GC FLU Quadrivalent

A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.

Intervention Type: BIOLOGICAL

Fluarix Tetra

A single dose administration of Fluarix Tetra will be through intramuscular injection.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Provision of signed and dated informed consent form

2. Either gender, aged 20 to 50 years old (inclusive)

3. Willing and able to comply with all the required study visits and follow-up defined by this protocol

4. Female subject with childbearing potential or male subject with female spouse/partner with childbearing potential must agree to use highly effective contraceptives from 15 days prior to vaccination until 60 days after vaccination. At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:

• Established use of oral, injected or implanted hormonal methods of contraception
• Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

Exclusion Criteria

1. With previous known or potential exposure to influenza virus within 12 weeks prior to vaccination

2. Received seasonal influenza vaccine (registered or investigational) within 24 weeks prior to vaccination

3. Received any vaccine other than seasonal influenza vaccine within 6 weeks prior to vaccination

4. Received other investigational products (including medications and vaccines) within 6 weeks prior to vaccination

5. Administered immunoglobulins and/or other blood products within the 12 weeks prior to vaccination

6. Known or suspected hypersensitivity to any component of vaccines (including egg proteins); or history of allergy to consumption of eggs

7. History of inflammatory or degenerative neurological disease (e.g., Guillain-Barre syndrome)

8. With confirmed or suspected immunosuppressive or immunodeficient condition (e.g. HIV infection), or received > 14 days of systemic steroid with equivalent dosage equal or over to 0.5 mg/kg/day prednisolone or other immune-modifying agents within 24 weeks prior to vaccination

9. Positive in HIV, HBsAg, or HCV test

10. With fever (defined as body temperature equal or over to 38 °C by any method) on the day of vaccination

11. With ongoing acute diseases or within the past 2 years serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject

12. Female subject who is lactating or has positive serum or urine pregnancy test at screening or vaccination

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Medigen Vaccine Biologics Corp.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Szu-Min Hsieh, MD

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Locations

National Taiwan University Hospital

Taipei, , Taiwan

Taipei Municipal Wan Fang Hospital

Taipei, , Taiwan

Tri-Service General Hospital

Taipei, , Taiwan

Linkou Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Countries

Taiwan

Other Identifiers

CT-QV-31

Identifier Type: -

Identifier Source: org_study_id